AERI Aerie Pharmaceuticals, Inc.

41.05
+0.4  (0.98%)
Previous Close 40.65
Open 40.70
Price To book 10.57
Market Cap 1.37B
Shares 33,382,000
Volume 160,262
Short Ratio 8.96
Av. Daily Volume 485,994

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536699
  2. 8-K - Current report 17515737
  3. 8-K - Current report 17515729
  4. 8-K - Current report 162067904
  5. 8-K - Current report 162057758

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
Roclatan - Mercury trials
Glaucoma
NDA Filing September 6, 2016 withdrawn due to third party manufacturing issues. NDA to be refiled towards the end of 1Q 2017.
Rhopressa
Glaucoma

Latest News

  1. Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research
  2. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
  4. Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
  5. Aerie (AERI) Rhopressa Regulatory Application Delayed Again
  6. Dow books 7th straight weekly gain in muted preholiday trade
  7. Markets Open Flat Heading Into the Holidays
  8. Aerie Pharmaceuticals' stock set to selloff after FDA inspection delay
  9. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  10. Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  11. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer
  13. Hedge Funds Aren’t Banking On PennyMac Mortgage Investment Trust (PMT)
  14. Should You Buy Aerie Pharmaceuticals Inc (AERI)?
  15. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  16. Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  17. Is Endologix, Inc. (ELGX) A Good Stock To Buy Right Now?
  18. Is DHT Holdings Inc (DHT) About to Sink? Hedge Funds Are Fleeing
  19. Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC
  20. Aerie Pharmaceuticals to Participate in Two Investor Conferences in December

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536699
  2. 8-K - Current report 17515737
  3. 8-K - Current report 17515729
  4. 8-K - Current report 162067904
  5. 8-K - Current report 162057758
  6. 8-K - Current report 162037619
  7. 8-K - Current report 161997800
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971193
  9. 8-K - Current report 161967805
  10. 8-K - Current report 161955516